26 citations
,
January 1987 in “Archives of Dermatology” In this study, topical minoxidil did not show an antiandrogenic effect on androgen-dependent cutaneous structures in the golden Syrian hamster, suggesting it likely does not have this role in humans either.
13 citations
,
September 1986 in “Archives of Dermatology” This study found that women with female pattern baldness often had a higher ratio of 3 alpha,17 beta-androstanediol glucuronide to sex hormone-binding globulin and lower serum sex hormone-binding globulin, possibly indicating minimal androgen excess.
32 citations
,
August 1985 in “Clinical endocrinology” This study concluded that spironolactone may be an effective therapy for a subgroup of hirsute patients, as it reduced plasma testosterone and improved certain hair growth measures.
138 citations
,
August 1985 in “Journal of The American Academy of Dermatology” Minoxidil promotes hair growth in male pattern baldness.
67 citations
,
July 1985 in “British journal of dermatology/British journal of dermatology, Supplement” This study found that males have significantly longer hair on their thighs compared to females, mainly due to a longer anagen phase and a greater rate of growth.
142 citations
,
February 1985 in “Fertility and sterility” This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.
55 citations
,
February 1985 in “Archives of Dermatology” In this randomized trial, topical minoxidil treatment resulted in cosmetically acceptable hair growth in 32% of men with hereditary male pattern baldness, with no serious side effects reported.
53 citations
,
January 1985 in “Acta obstetricia et gynecologica Scandinavica” This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.
101 citations
,
January 1985 in “British Journal of Dermatology” This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.
43 citations
,
July 1984 in “Clinical and Experimental Dermatology” This study found that women with common baldness treated with cyclical antiandrogen therapy for 52 weeks experienced increased hair density and a higher percentage of hairs in the anagen growth phase.
46 citations
,
June 1983 in “Cleveland Clinic Journal of Medicine” In this study, women with diffuse alopecia were found to have higher serum levels of adrenal androgen DHEAS, which may contribute to disrupted scalp hair growth.
39 citations
,
January 1980 in “Dermatology” In this study, cyproterone acetate with ethinyl estradiol effectively treated acne, hirsutism, and alopecia in women, with the highest success in acne and rare side effects similar to estrogen contraceptives.
60 citations
,
September 1979 in “Fertility and sterility” This study found that spironolactone reduced testosterone production and urinary 17-ketosteroid excretion, leading to a decrease in hair growth rate and a change in hair texture in women.
666 citations
,
September 1977 in “British Journal of Dermatology” This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.